Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 13, 2022American Journal of HematologyOpen Access

Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management

View Full Paper
Ask AI
Bookmark
Share

Authors

AHAlexandra C. HristovTTTrilokraj TejasviRWRyan A. Wilcox

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hristov et al. (2022) studied this question.

synapsesocial.com/papers/69e08132a4fa27a5614591a2https://doi.org/10.1002/ajh.26760
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Acetylation of p53 at Lysine 373/382 by the Histone Deacetylase Inhibitor Depsipeptide Induces Expression of p21<sup>Waf1/Cip1</sup>2006 · 276 citations
  2. 2Bexarotene therapy for mycosis fungoides and Sézary syndrome2009 · 122 citations
  3. 3Treatment of Cutaneous T-Cell Lymphoma With Combined Immunomodulatory Therapy2002 · 121 citations
  4. 4Histone deacetylase (HDAC) inhibitor activation of p21 <sup>WAF1</sup> involves changes in promoter-associated proteins, including HDAC12004 · 556 citations
  5. 5Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma2008 · 301 citations